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Abstract 
Objective: The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified 
Released Controlled Evaluation (ADVANCE) trial reported that intensive glucose control 
prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes but uncertainty 
about the balance between risks and benefits exists. Here we examine the long-term effects of 
intensive glucose control on risk of ESKD and other outcomes. 
Research Design and Methods: Survivors, previously randomized to intensive or standard 
glucose control, were invited to participate in post-trial follow-up. ESKD, defined as the need 
for dialysis or kidney transplantation, or death due to kidney disease, was documented 
overall and by baseline CKD stage, along with hypoglycemic episodes, major cardiovascular 
(CV) events and death from other causes. 
Results: 8494 ADVANCE participants were followed for a median of 5.4 additional years. 
In-trial HbA1c differences disappeared by the first post-trial visit. The in-trial reductions in 
the risk of ESKD (7 vs 20 events, HR 0.35, p=0.02) persisted after 9.9 years of overall 
follow-up (29 vs 53 events, HR 0.54, p<0.01). These effects were greater in earlier 
stage CKD (p=0.04) and at lower baseline systolic blood pressure levels (p=0.01). The effects 
of glucose lowering on the risks of death, CV death or major CV events did not differ by 
levels of kidney function (p>0.26). 
Conclusions: Intensive glucose control was associated with a long-term reduction in ESKD, 
without evidence of any increased risk of CV events or death. These benefits were greater 
with preserved kidney function and with well-controlled blood pressure. 
(ADVANCE-ON Clinical Trials.gov NCT00949286) 
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Diabetes mellitus has surpassed glomerulonephritis as the commonest cause of end stage 
kidney disease (ESKD) in the developed world, and many developing countries (1). Although 
only a minority of individuals with diabetes will develop nephropathy and ESKD, the rapidly 
increasing number of people with type 2 diabetes is projected to result in a substantial 
increase in the numbers requiring renal replacement therapy, in turn leading to major growth 
in economic costs for health systems (2). In addition, CKD is recognized as one of the 
strongest risk factors for cardiovascular disease, particularly in the presence of diabetes, 
conferring a substantial increase in the risk of death and hospitalization (3). 
 
Despite the implementation of ‘best practice’ standards of care for lifestyle modification, 
blood pressure lowering and renin-angiotensin-aldosterone system (RAAS) blockade, there 
remains a high level of progression to ESKD for those with diabetic kidney disease (4, 5). 
Although a number of promising novel therapies are being studied in early clinical trials, 
none are as yet available (6).  This has resulted in renewed interest in the role of intensive 
glucose control.  Post-trial follow-up of the United Kingdom Prospective Diabetes Study 
(UKPDS) cohort of newly diagnosed patients with type 2 diabetes (7) and the Diabetes 
Control and Complications Trial (DCCT) cohort of young patients with type 1 diabetes (8), 
showed a sustained benefit for microvascular complications, beyond the period of intensive 
glucose control. In these studies, microvascular complications were composites of retinal 
photocoagulation, microalbuminuria, and neuropathy with few, if any, patients developing 
ESKD or dying from renal disease (9).   
 
We have previously reported, in the Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation (ADVANCE) study, that intensive 
glucose control in patients with type 2 diabetes significantly reduced the risk of a range of 
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renal outcomes including new or worsening nephropathy and ESKD (10). However, the small 
number of ESKD events observed during the trial limited the strength of the conclusions. In 
addition, the safety of intensive glucose control in the presence of CKD has been questioned, 
with the ACCORD trial (11) recently reporting that its intensive glucose lowering strategy 
increased the risk of cardiovascular and all-cause death among participants with CKD, but 
not in those with normal kidney function. 
 
The outcomes of the 6-year post-trial follow-up of the ADVANCE trial cohort, also known as 
the ADVANCE-ObservatioNal study (ADVANCE-ON), were recently published (12). Here 
we report on further analyses that examine the long-term effects of the intensive glucose 
control strategy on ESKD, CV events and death, including analyses across different levels of 
kidney function, in patients with type 2 diabetes.  
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Research Design and Methods 
ADVANCE trial 
The original trial design and methods have been published previously (13, 14). Briefly, 
11,140 individuals with type 2 diabetes aged 55 years and older, with at least one additional 
risk factor for cardiovascular disease were enrolled from 215 centers in 20 countries between 
2001 and 2003.  Patients were randomly assigned in a 2x2 factorial design to 1) a gliclazide 
modified release (MR)-based intensive glucose control regimen, aiming for an HbA1c level 
of 6·5% or lower, or to standard glucose control based on local guidelines of participating 
countries, and 2) to a single pill (fixed dose) combination of perindopril and indapamide 
(4mg/1·25mg) or matching placebo, after a 6-week active run-in period. The last trial visits 
for the glucose control comparison were completed in January 2008, after a median follow-up 
period of 5.0 years and the results for the blood pressure (15) and glucose (14) interventions 
were reported then.  All patients then ceased their randomized interventions and returned to 
usual care through their treating physician.  
 
ADVANCE-ON study 
ADVANCE-ON was a post-trial follow-up study of surviving ADVANCE trial patients.  
All local ADVANCE trial sites were invited to participate in ADVANCE-ON and 172 of 215 
sites (80%) agreed.  After approval by the local ethics review boards of each participating 
site, all surviving trial patients at those sites were invited to enter post-trial follow-up.  In 
January 2010, annual post-trial visits commenced.  At the first post-trial visit informed 
consent was obtained and a standardized questionnaire completed on the occurrence of all 
study outcomes of interest and all medications taken.  A random subset of 2000 patients 
balanced across regions and across the prior randomized treatment arms, was also invited to 
undergo assessment of HbA1c, fasting blood glucose, blood pressure, weight, serum 
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creatinine and urinary albumin:creatinine ratio at the first post-trial visit, to determine 
whether in-trial differences persisted. For patients known to have died after the final in-trial 
visit, the cause and date of death were recorded. For patients unwilling or unable to attend 
study visits in person, follow-up was conducted by telephone, home visit or information 
provided by the primary care physician, other health care providers or next of kin. At annual 
visits patients completed a questionnaire on medication taken and the occurrence of study 
outcomes.  In addition, at the final visits, that occurred between 1 January 2013 and 28 
February 2014, patients attending visits in person (whether or not they had completed 
assessment at the first visit) were invited to undergo re-assessment of HbA1c, fasting blood 
glucose, weight, blood pressure, serum creatinine and urinary albumin:creatinine ratio.  
 
Study outcomes 
The pre-specified renal outcomes for ADVANCE-ON were ESKD (requirement for dialysis 
or renal transplantation) and death due to renal disease. Other outcomes included death due to 
any cause, major cardiovascular events (myocardial infarction, stroke or cardiovascular 
death, examined jointly and separately), and major hypoglycemia. It was not possible to 
replicate the outcome “new or worsening nephropathy” as defined in the original trial 
(development of macroalbuminuria (UACR>300μg/mg or 33.9mg/mmol/L), doubling of 
serum creatinine to a level of 200μmol/L (2.26mg/dl), ESKD and death due to renal disease 
because levels of serum creatinine and urinary albumin were only measured in a subgroup of 
patients during post-trial follow-up. Outcomes occurring during post-trial follow-up were as 
reported by the study centers using the standardized definitions used during the trial, without 
central adjudication.  
 
Statistical methods 
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Analyses were conducted according to the initial treatment assignment. Treatment effects 
were examined using cumulative incidence survival curves and Cox proportional hazards 
models. Patients were censored at the first relevant end-point, the date of death, date of last 
visit (for those still alive) or date last known to be alive for those whose vital status was 
unknown at the end of the study (February 28, 2014). Hazard ratios were estimated for the in-
trial period and over the entire period of follow-up.  An additional post-hoc observational 
analysis was performed for the post-trial period alone. Serial hazard ratios (HRs) with 95% 
confidence intervals (CI) were estimated at the end of each calendar year of post-trial follow-
up. The homogeneity of treatment effects for pre-specified subgroups was tested by adding an 
interaction term to the relevant Cox models.  
 
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to 
calculate the eGFR. For analyses by baseline CKD status, participants were divided into 
CKD stage 1 (eGFR ≥90 ml/min/1.73m2 and urine albumin/creatinine ratio ≥30 mg/mg); 
CKD stage 2 (eGFR between 60 and 89 ml/min/1.73m2 and urine albumin/creatinine ratio 
≥30 mg/mg), CKD Stage ≥ 3 (eGFR less than 60 ml/min/1.73m2 with or without albuminuria, 
and those without CKD (eGFR ≥60 ml/min/1.73m2 and urine albumin/creatinine ratio <30 
mg/mg) (16).  
 
The analyses were performed with SAS (version 9.2). All tests were two-sided and p values 
less than 0.05 were considered to indicate statistical significance. The protocol pre-specified 
that no adjustments would be made for the multiple statistical testing (12). In light of this the 
findings were interpreted with the appropriate degree of caution. 
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Results 
Of 10,082 patients originally assigned to the randomized treatments and alive at the end of 
the trial, 8,494 (4283 vs. 4211, intensive vs. standard glucose control) entered post-trial 
follow-up and 5131 (2638 vs. 2493, intensive vs. standard) of those still alive completed a 
visit during the final year of the study (12). The median in-trial, post-trial and total follow-up 
periods were 5.0 years, 5.4 years and 9.9 years respectively (Supplementary Figure 1). As 
previously reported the pre-randomisation characteristics of the original glucose control trial 
population and of the follow-up study cohort were similar (17) .  
 
Use of glucose lowering and other therapies 
During post-trial follow-up there was less use of sulfonylureas (including gliclazide MR), 
metformin, glitazones and α-glucosidase inhibitors but more use of insulin and other glucose 
lowering therapies (including gliptins and glucagon-like peptide 1 analogues) in both the 
intensive and standard glucose control groups, irrespective of CKD stage (Supplementary 
Tables S1-S3). The use of blood pressure lowering agents, statins and anti-platelet agents was 
also comparable across the groups, irrespective of the CKD stage (Supplementary Tables S1-
S3). 
 
Glycemic control 
The mean difference in HbA1c (0.67% 95%CI 0.64, 0.70, p<0.001) observed at the end of 
randomized therapy was lost when measured on average 2.9 years later at the first post-trial 
visit (0.08%, 95%CI -0.07, 0.22, p=0.29).  There was a rise in HbA1c in the intensive control 
group approaching that observed in the standard control group.  The HbA1c levels of the two 
groups converged at the first post-trial visit (7.3% vs 7.3%, p=0.29) and remained similar at 
the last post-trial visit (12).  
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ESKD or Renal Death  
During the in-trial period, 27 patients recorded ESKD events and 37 patients died due to renal 
causes. During the post-trial period an additional 55 patients recorded ESKD events and 64 
patients died due to renal causes (Table 1).  
 
The significant reduction in the risk of ESKD observed with intensive glucose control during 
the in-trial period (7 vs 20 events, HR 0.35, 95% confidence interval (CI) 0.15 to 0.83, 
p=0.02) persisted after a total of 9.9 years of follow-up (29 vs 53, HR 0.54, 95%CI 0.34 to 
0.85, p<0.01) (Figure 1).  
 
Subgroup analyses examining the effects of intensive glucose control by patient 
characteristics at trial baseline suggested no heterogeneity with similar risk reductions for 
males and females, those aged above and below 65 years, and those with HbA1c levels above 
and below the median (7.2%) (Figure 2).  
 
In contrast, heterogeneity was observed for patients according to CKD stage, as well as 
patients with systolic blood pressure (BP) levels below or above 140 mmHg (Figure 2, both p 
< 0.05). A graded reduction in the strength of the effect of intensive glucose control on 
ESKD was seen as CKD stage increased (Figure 2, p heterogeneity=0.04). In patients at trial 
baseline with systolic BP levels below 140 mmHg the risk reduction in ESKD was greater 
than in those with systolic BP levels above 140 mmHg (HR 0.19, 95%CI 0.06 to 0.55 vs. HR 
0.77, 95%CI 0.46 to 1.30 respectively, p heterogeneity=0.01) (Figure 2).   
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The non-significant effect on the risk of death due to renal disease observed during the in trial 
period (HR 0.85, 95%CI 0.45 to 1.62) remained similar after a total of 9.9 years of follow-up 
(HR 0.89, 95%CI 0.60 to 1.31) (Figure 1).  
 
Absolute renal effects 
Across the entire population over 9.9 years, 194 participants would need to be treated 
with intensive glucose control to prevent one ESKD event (Table 1). Further, the NNT 
by CKD stage was 109 for CKD stage 1 and 2 and 393 for CKD stage 3 or greater. The 
NNT by SBP was 120 for baseline SBP less than 140mmHg and 368 for baseline SBP 
≥140mmHg (Table 1).   
 
Other outcomes 
The rate of major hypoglycemia was low overall and the increase in risk for the 
intensive versus the standard glucose control group observed during the trial was no 
longer evident after post-trial follow-up (Supplementary figure 2). The absolute risk of 
hypoglycemia tended to be slightly higher for the group with CKD Stage 3 or greater as 
compared to no CKD or CKD stage 1 and 2 irrespective of the original randomized 
groups. However, the increase in risk for the intensive versus standard glucose control 
groups was similarly no longer evident for subgroups of patients defined by CKD stage 
after post-trial follow-up (overall study period p for heterogeneity 0.92). 
 
Intensive glucose control had no clear effects on overall all-cause mortality, 
cardiovascular death, major cardiovascular events, myocardial infarction or stroke. In 
addition, there was no evidence that baseline CKD status had any impact on the effect 
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of intensive glucose control on these outcomes (Figure 3, all p-heterogeneity >0.2) 
during the in-trial period or during extended follow-up. 
 
Conclusions 
 
After following the ADVANCE trial cohort for a total of 9.9 years, we show that a prior 
period of intensive glucose control continues to protect against the development of ESKD in 
patients with type 2 diabetes. The patients who appear to benefit the most are those with 
preserved kidney function, with intermediate effects in the group with CKD stage 1 or 2, and 
lesser effects in participants with CKD stage 3 or greater at baseline. Greater reductions in 
ESKD were also observed in participants with better blood pressure control at baseline 
(systolic BP <140mmHg). Importantly, the impact of intensive glucose control on mortality 
or major cardiovascular events was not adversely affected by CKD at baseline, either during 
the trial or overall study follow-up. 
 
Our data provide the strongest evidence to date regarding the renal benefits of intensive 
glucose lowering, and are consistent with data on intermediate outcomes from other studies. 
These include the Epidemiology of Diabetes Interventions and Control (EDIC) study in a 
population of younger individuals with type 1 diabetes, which reported that a prior period of 
intensive glucose control reduced the long-term risk of developing renal impairment (eGFR 
below 60ml/min/1.73m2) by 50% after a median follow-up of 22 years (18). However, in that 
study a clear benefit for ESKD was not demonstrated, most likely because few ESKD events 
were recorded.  Similarly the long-term follow-up of the UKPDS cohort of newly diagnosed 
patients with type 2 diabetes reported persistent microvascular (eye and renal events) and 
emerging macrovascular benefits in those previously assigned to intensive glucose lowering, 
with benefits for kidney failure defined by lower risk of increases in serum creatinine to more 
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than 250 μmol/L. The ACCORD study reported a numerically lower risk of renal failure with 
intensive glucose lowering, however this did not achieve statistical significance (19). The 
results regarding the effects on ESKD in the long-term follow-up of the ACCORD trial are 
awaited with interest. 
 
In ADVANCE the difference in the rate of ESKD events between the intensive and the 
standard glucose control groups took more than 2 years to emerge, but then persisted (with a 
further numerically lower number of events) to the end of the overall study period, even after 
the HbA1c converged. The risk reduction for ESKD events observed in ADVANCE-ON 
likely goes beyond a simple carry forward of the effects observed during the original trial 
period. As the development of ESKD often takes decades to appear after the onset of diabetes 
mellitus, it might well be anticipated that slowing of this process would take years to become 
evident especially if it requires abrogation of diabetes-induced structural changes in the 
glomerulus (20, 21) In contrast, the effects of RAS blockade and BP lowering are likely to 
have a more rapid onset and offset in response to treatment.  
 
Our results highlight the importance of commencing intensive glucose control before diabetic 
kidney disease develops as lesser renal benefit was observed in participants with an 
established reduction in kidney function, suggesting that the relative contribution of glucose 
dependent and glucose independent pathways may vary at different levels of kidney function. 
The lesser benefit in those with moderately reduced kidney function (CKD stage 3 or greater) 
may indicate that glucose independent mechanisms of renal progression are predominant, in 
the later stages of the disease (22). In the subgroup of patients without baseline CKD the 
benefits for ESKD were maintained in the long-term suggesting the earlier period of intensive 
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glucose control may have prevented structural changes in both the glomeruli and 
tubulointerstitium when renal function was relatively intact.  
 
Similar differences were found in subgroups defined by baseline BP, with a much greater 
reduction in ESKD by the end of overall follow-up in participants whose systolic BP at 
baseline was below the hypertensive range (<140mmHg). These findings also support the 
premise that greater benefits will be obtained through intensive glucose control earlier in the 
life course of the patient with type 2 diabetes. While a recent report has raised concerns 
regarding a possible increase in the risk of adverse outcomes in the presence of CKD with 
intensive glucose control, particularly risk of death (11), we found no evidence for this. 
Collectively, these data support early intensive glucose control and optimal blood pressure 
levels for the prevention of long-term renal complications in individuals with type 2 diabetes.   
  
An interesting finding was the lack of consistency in the results for ESKD and renal death. A 
low number of events is one reason. Death purely attributed to renal causes is less common 
than death due to cardiovascular or cerebrovascular causes. However, establishing cause of 
death during any clinical trial may be challenging. During the ADVANCE trial renal death 
was adjudicated whereas during the ADVANCE-ON post-trial follow-up renal death could 
not be adjudicated. In addition, it may be difficult to ascertain whether a death is due to 
progressive kidney failure, inter-current cardiovascular event, or some combination of the 
two. This could result in greater uncertainty as to the effects on this outcome as compared to 
that of ESKD, which is simpler to define as requirement for dialysis or renal transplantation. 
Indeed other clinical trials such as RENAAL and IDNT have similarly not been able to 
identify beneficial effects on renal death (4, 5) It was also not possible to report progression 
or regression of albuminuria or doubling of serum creatinine as occurred in the original trial 
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because serum creatinine levels and urinary albumin-to-creatinine ratios at the first post-trial 
visit were only available and able to be collected for a subset of participants (13).  
 
A clear strength of this study is the long-term follow-up of a large and diverse patient 
population with type 2 diabetes.  The limitations include non-adjudicated renal endpoints and 
the lack of complete biochemical data for all participants during the post-trial follow-up. 
Additionally, although the number of ESKD events tripled during the post-trial period, the 
number of events remained small. This limitation is especially important to bear in mind 
when interpreting differences between subgroups and between stages of CKD. 
 
Our data build on a growing body of evidence indicating an important role for intensive 
glucose control in limiting the progression of kidney disease and in curbing the growing 
number of patients around the world with type 2 diabetes requiring dialysis or transplantation 
as a result of diabetic kidney disease.  
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Tables 
 
Table 1: Comparison of number need to treat (NNT) over 5 years and 9.9 years to prevent one ESKD event overall 
Population and subgroup 
5 years follow-up period 9.9 years follow-up period 
Participants 
Annual event rate NNT to prevent one 
ESKD event over 5 
years 
Participants 
Annual event rate NNT to prevent 
one ESKD over 
9.9 years 
Standard Intensive Standard Intensive 
N (%) (%) (%) N (%) (%) (%) 
Overall 11,140 (100) 0.075 0.026 410 11,140 (100) 0.112 0.061 194 
No CKD 5935 (53.3) 0.014 0.007 2839 5935 (53.3) 0.046 0.008 259 
CKD stage 1&2 2404 (21.6) 0.106 0.035 283 2404 (21.6) 0.14 0.048 109 
CKD stage ≥3 2256 (20.3) 0.129 0.039 220 2256 (20.3) 0.232 0.207 393 
         
SBP < 140 4704 (42.2) 0.053 0.009 453 4704 (42.2) 0.103 0.019 120 
SBP ≥ 140 6435 (57.8) 0.091 0.039 384 6435 (57.8) 0.12 0.092 368 
 
Abbreviation: eGFR, estimated glomerular filtration rate (ml/min/1.73m2); ESKD, end stage kidney disease, NNT, number need to treat. 
NNT over 5 years=1/(annual event rate in standard * 5 - annual event rate in intensive *5) 
NNT over 10 years=1/(annual event rate in standard * 10 - annual event rate in intensive *10) 
*The event rate in intensive arm is higher than it in standard arm, so the NNT is calculated as negative value and I put (-) here to say not applicable. 
Note: Stage I CKD was defined as eGFR≥90 ml/min/1.73m2 and urine albumin/creatinine ratio≥30 mg/mg; Stage II CKD was defined as eGFR between 
60 and 89 ml/min/1.73m2 and urine albumin/creatinine ratio ≥30 mg/mg; Stage ≥ III was defined as eGFR less than 60 ml/min/1.73m2 with or without 
albuminuria. Mild CKD included patients with Stage I and II, and moderate CKD included patients with Stage III CKD. eGFR is calculated using EPI-
CKD formula. 
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Figure legends 
 
Figure 1. Summary plot showing the effects of intensive glucose lowering compared with 
standard glucose lowering on EKSD and/or death due to renal cause, during the in-trial, post 
trial and the overall study periods of follow-up.  CI, Confidence interval; ESKD, end stage 
kidney disease; Renal death, death due to renal causes.  
 
Figure 2. Subgroup analyses by baseline characteristics for the outcome of end stage kidney 
disease. The p-value provided represents test for heterogeneity between subgroups. CI, 
confidence interval; CKD, chronic kidney disease; ESKD, end stage kidney disease; HbA1c, 
glycated hemoglobin A1c.  
 
Figure 3. The Forest plots of all-cause mortality and major cardiovascular events by 
randomised subgroups for the A) In-trial period and B) Overall study period. The p-value 
provided represents test for heterogeneity between subgroups. CI, confidence interval; CKD, 
chronic kidney disease; ESKD, end stage kidney disease; HbA1c, glycated hemoglobin A1c.  
 
Supplementary Figure 1. A schematic representation of the original ADVANCE study and 
follow-up observational, ADVANCE-ON study timeline.  * Final visit between 1 January 
2013 and 28 February 2014.  
 
Supplementary Figure 2. Forest plots of severe hypoglycemia events by randomized 
subgroups for the “in-trial” ADVANCE period (left half) and for the overall study period 
(right half). The p-value provided represents the test for heterogeneity between subgroups. 
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CI, confidence interval; CKD, chronic kidney disease; ESKD, end stage kidney disease; 
HbA1c, glycated hemoglobin A1c.  
